Evidence map›Paper›PMID 31242463›Full record

ArticleJournal of molecular endocrinology2019

Glucose-dependent GPER1 expression modulates tamoxifen-induced IGFBP-1 accumulation.

Yan Zheng, Kevin D Houston

Open access · hybridAbstract read
In one paragraph

Article in Journal of molecular endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Investigating differences between tamoxifen resistant and sensitive breast cancer cells with flow cytometry.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yan ZhengDepartment of Chemistry and Biochemistry, New Mexico State University, Las Cruces, New Mexico, USA.
Kevin D HoustonDepartment of Chemistry and Biochemistry, New Mexico State University, Las Cruces, New Mexico, USA.
New Mexico State University · US

Funding

NM-INBRE Sequencing and Bioinformatics CoreP20GM103451 · NIGMS · NEW MEXICO STATE UNIVERSITY LAS CRUCES · PI Charlotte C. Gard · 2012 to 2026
$61.2M
GPER1-dependent regulation of IGF-1R in tamoxifen treated breast cancer cellsSC1GM127175 · NIGMS · NEW MEXICO STATE UNIVERSITY LAS CRUCES · PI HOUSTON, KEVIN D. · 2019 to 2022
$1.5M
NIGMS NIH HHS P20 GM103451NIGMS NIH HHS SC1 GM127175
6 · The paper itself

Abstract

G protein-coupled estrogen receptor 1 (GPER1) is a seven-transmembrane receptor that mediates rapid cell signaling events stimulated by estrogens. While the role that GPER1 has in the modulation of E2-responsive tissues and cancers is well documented, the molecular mechanisms that regulate GPER1 expression are currently not well defined. The recently identified GPER1-dependent mechanism of tamoxifen action in breast cancer cells underscores the importance of identifying mechanisms that regulate GPER1 expression in this cell type. We hypothesized that GPER1 expression in breast cancer cells is sensitive to [D-glucose] and provide data showing increased GPER1 expression when cells were cultured in low [D-glucose]. To determine if the observed accumulation of GPER1 was AMP-activated protein kinase (AMPK)-dependent, small molecule stimulation or inhibition of AMPK was performed. AMPK inhibition decreased GPER1 accumulation in cells grown in low [D-glucose] while the AMPK-activating compound AICAR increased GPER1 accumulation in cells grown in high [D-glucose] media. Additionally, transfection of cells with a plasmid expressing constitutively active AMPK resulted in increased GPER1 accumulation. To determine if [D-glucose]-dependent GPER1 accumulation altered breast cancer cell response to tamoxifen, cells grown in the presence of decreasing [D-glucose] were co-treated with tamoxifen and IGFBP-1 transcription was measured. The results from these experiments reveal that D-glucose deprivation increased GPER1-mediated and tamoxifen-induced IGFBP-1 transcription suggesting that [D-glucose] may increase breast cancer cell sensitivity to tamoxifen. Taken together, these results identify a previously unknown mechanism that regulates GPER1 expression that modifies one aspect tamoxifen action in breast cancer cells.

Indexed as

Adenylate KinaseAnimalsBreast NeoplasmsCell Line, TumorEnzyme ActivationFemaleGene Expression Regulation, NeoplasticGlucoseHumansInsulin-Like Growth Factor Binding Protein 1PhosphorylationRatsReceptors, EstrogenReceptors, G-Protein-CoupledTamoxifenTranscription, GeneticAdenylate KinaseGlucoseGPER1 protein, humanIGFBP1 protein, humanInsulin-Like Growth Factor Binding Protein 1Receptors, EstrogenReceptors, G-Protein-CoupledTamoxifenbreast cancerestrogen receptorsIGFBP-1metabolism

Identifiers

PMID31242463
PMCPMC6598863
OpenAlexW2954739471

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.